MARKERS ASSOCIATED WITH CHRONIC LYMPHOCYTIC LEUKEMIA PROGNOSIS AND PROGRESSION

摘要

The present invention provides methods and devices related to markers (or biomarkers) associated with chronic lymphocytic leukemia (CLL). Examples of these markers include drivers of CLL progression. The invention contemplates, inter alia, detecting the clonal, including subclonal, profile of CLL in a subject and the presence (or absence) of subclonal driver mutations, and utilizing this information in predicting disease progression, need, timing and/or nature of treatment regimen, and likelihood and frequency of relapse.

主权项

1. A method of determining a treatment regimen for a subject having chronic lymphocytic leukemia (CLL) comprising identifying a mutation in the SF3B1 gene in a subject sample, wherein the presence of one or more mutations in the SF3B1 gene indicates that the subject should receive an alternative treatment regimen.